Anticorps monoclonaux humanisés : Questions médicales fréquentes

{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Anticorps monoclonaux humanisés : Questions médicales les plus fréquentes", "headline": "Anticorps monoclonaux humanisés : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Anticorps monoclonaux humanisés : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-07-03", "dateModified": "2025-12-25", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Anticorps monoclonaux humanisés" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Anticorps monoclonaux", "url": "https://questionsmedicales.fr/mesh/D000911", "about": { "@type": "MedicalCondition", "name": "Anticorps monoclonaux", "code": { "@type": "MedicalCode", "code": "D000911", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.224" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Adalimumab", "alternateName": "Adalimumab", "url": "https://questionsmedicales.fr/mesh/D000068879", "about": { "@type": "MedicalCondition", "name": "Adalimumab", "code": { "@type": "MedicalCode", "code": "D000068879", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.224.200.250" } } }, { "@type": "MedicalWebPage", "name": "Alemtuzumab", "alternateName": "Alemtuzumab", "url": "https://questionsmedicales.fr/mesh/D000074323", "about": { "@type": "MedicalCondition", "name": "Alemtuzumab", "code": { "@type": "MedicalCode", "code": "D000074323", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.224.200.375" } } }, { "@type": "MedicalWebPage", "name": "Basiliximab", "alternateName": "Basiliximab", "url": "https://questionsmedicales.fr/mesh/D000077552", "about": { "@type": "MedicalCondition", "name": "Basiliximab", "code": { "@type": "MedicalCode", "code": "D000077552", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.224.200.407" } } }, { "@type": "MedicalWebPage", "name": "Bévacizumab", "alternateName": "Bevacizumab", "url": "https://questionsmedicales.fr/mesh/D000068258", "about": { "@type": "MedicalCondition", "name": "Bévacizumab", "code": { "@type": "MedicalCode", "code": "D000068258", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.224.200.438" } } }, { "@type": "MedicalWebPage", "name": "Brentuximab védotine", "alternateName": "Brentuximab Vedotin", "url": "https://questionsmedicales.fr/mesh/D000079963", "about": { "@type": "MedicalCondition", "name": "Brentuximab védotine", "code": { "@type": "MedicalCode", "code": "D000079963", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.224.200.469" } } }, { "@type": "MedicalWebPage", "name": "Cétuximab", "alternateName": "Cetuximab", "url": "https://questionsmedicales.fr/mesh/D000068818", "about": { "@type": "MedicalCondition", "name": "Cétuximab", "code": { "@type": "MedicalCode", "code": "D000068818", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.224.200.750" } } }, { "@type": "MedicalWebPage", "name": "Daclizumab", "alternateName": "Daclizumab", "url": "https://questionsmedicales.fr/mesh/D000077561", "about": { "@type": "MedicalCondition", "name": "Daclizumab", "code": { "@type": "MedicalCode", "code": "D000077561", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.224.200.766" } } }, { "@type": "MedicalWebPage", "name": "Dénosumab", "alternateName": "Denosumab", "url": "https://questionsmedicales.fr/mesh/D000069448", "about": { "@type": "MedicalCondition", "name": "Dénosumab", "code": { "@type": "MedicalCode", "code": "D000069448", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.224.200.782" } } }, { "@type": "MedicalWebPage", "name": "Gemtuzumab", "alternateName": "Gemtuzumab", "url": "https://questionsmedicales.fr/mesh/D000079982", "about": { "@type": "MedicalCondition", "name": "Gemtuzumab", "code": { "@type": "MedicalCode", "code": "D000079982", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.224.200.790" } } }, { "@type": "MedicalWebPage", "name": "Inotuzumab ozogamicine", "alternateName": "Inotuzumab Ozogamicin", "url": "https://questionsmedicales.fr/mesh/D000080045", "about": { "@type": "MedicalCondition", "name": "Inotuzumab ozogamicine", "code": { "@type": "MedicalCode", "code": "D000080045", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.224.200.794" } } }, { "@type": "MedicalWebPage", "name": "Ipilimumab", "alternateName": "Ipilimumab", "url": "https://questionsmedicales.fr/mesh/D000074324", "about": { "@type": "MedicalCondition", "name": "Ipilimumab", "code": { "@type": "MedicalCode", "code": "D000074324", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.224.200.798" } } }, { "@type": "MedicalWebPage", "name": "Natalizumab", "alternateName": "Natalizumab", "url": "https://questionsmedicales.fr/mesh/D000069442", "about": { "@type": "MedicalCondition", "name": "Natalizumab", "code": { "@type": "MedicalCode", "code": "D000069442", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.224.200.813" } } }, { "@type": "MedicalWebPage", "name": "Nivolumab", "alternateName": "Nivolumab", "url": "https://questionsmedicales.fr/mesh/D000077594", "about": { "@type": "MedicalCondition", "name": "Nivolumab", "code": { "@type": "MedicalCode", "code": "D000077594", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.224.200.829" } } }, { "@type": "MedicalWebPage", "name": "Omalizumab", "alternateName": "Omalizumab", "url": "https://questionsmedicales.fr/mesh/D000069444", "about": { "@type": "MedicalCondition", "name": "Omalizumab", "code": { "@type": "MedicalCode", "code": "D000069444", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.224.200.844" } } }, { "@type": "MedicalWebPage", "name": "Palivizumab", "alternateName": "Palivizumab", "url": "https://questionsmedicales.fr/mesh/D000069455", "about": { "@type": "MedicalCondition", "name": "Palivizumab", "code": { "@type": "MedicalCode", "code": "D000069455", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.224.200.860" } } }, { "@type": "MedicalWebPage", "name": "Panitumumab", "alternateName": "Panitumumab", "url": "https://questionsmedicales.fr/mesh/D000077544", "about": { "@type": "MedicalCondition", "name": "Panitumumab", "code": { "@type": "MedicalCode", "code": "D000077544", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.224.200.864" } } }, { "@type": "MedicalWebPage", "name": "Ranibizumab", "alternateName": "Ranibizumab", "url": "https://questionsmedicales.fr/mesh/D000069579", "about": { "@type": "MedicalCondition", "name": "Ranibizumab", "code": { "@type": "MedicalCode", "code": "D000069579", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.224.200.868" } } }, { "@type": "MedicalWebPage", "name": "Trastuzumab", "alternateName": "Trastuzumab", "url": "https://questionsmedicales.fr/mesh/D000068878", "about": { "@type": "MedicalCondition", "name": "Trastuzumab", "code": { "@type": "MedicalCode", "code": "D000068878", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.224.200.875" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Ado-trastuzumab emtansine", "alternateName": "Ado-Trastuzumab Emtansine", "url": "https://questionsmedicales.fr/mesh/D000080044", "about": { "@type": "MedicalCondition", "name": "Ado-trastuzumab emtansine", "code": { "@type": "MedicalCode", "code": "D000080044", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.224.200.875.500" } } } ] }, { "@type": "MedicalWebPage", "name": "Ustékinumab", "alternateName": "Ustekinumab", "url": "https://questionsmedicales.fr/mesh/D000069549", "about": { "@type": "MedicalCondition", "name": "Ustékinumab", "code": { "@type": "MedicalCode", "code": "D000069549", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.224.200.937" } } } ], "about": { "@type": "MedicalCondition", "name": "Anticorps monoclonaux humanisés", "alternateName": "Antibodies, Monoclonal, Humanized", "code": { "@type": "MedicalCode", "code": "D061067", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Mika K Kaneko", "url": "https://questionsmedicales.fr/author/Mika%20K%20Kaneko", "affiliation": { "@type": "Organization", "name": "Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Japan." } }, { "@type": "Person", "name": "Yukinari Kato", "url": "https://questionsmedicales.fr/author/Yukinari%20Kato", "affiliation": { "@type": "Organization", "name": "Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Japan." } }, { "@type": "Person", "name": "Hiroyuki Suzuki", "url": "https://questionsmedicales.fr/author/Hiroyuki%20Suzuki", "affiliation": { "@type": "Organization", "name": "Department of Molecular Pharmacology, Tohoku University Graduate School of Medicine, Sendai, Japan." } }, { "@type": "Person", "name": "Teizo Asano", "url": "https://questionsmedicales.fr/author/Teizo%20Asano", "affiliation": { "@type": "Organization", "name": "Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Japan." } }, { "@type": "Person", "name": "Tomohiro Tanaka", "url": "https://questionsmedicales.fr/author/Tomohiro%20Tanaka", "affiliation": { "@type": "Organization", "name": "Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Japan." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "A humanized monoclonal antibody targeting protein a promotes opsonophagocytosis of Staphylococcus aureus in human umbilical cord blood.", "datePublished": "2023-07-16", "url": "https://questionsmedicales.fr/article/37455161", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.vaccine.2023.07.018" } }, { "@type": "ScholarlyArticle", "name": "Therapeutic, Humanized Monoclonal Antibody Exhibits Broad Binding and Protective Efficacy against Acinetobacter baumannii.", "datePublished": "2023-02-28", "url": "https://questionsmedicales.fr/article/36853012", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1128/aac.00086-23" } }, { "@type": "ScholarlyArticle", "name": "Anti-C1s humanized monoclonal antibody SAR445088: A classical pathway complement inhibitor specific for the active form of C1s.", "datePublished": "2023-05-04", "url": "https://questionsmedicales.fr/article/37149117", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.clim.2023.109629" } }, { "@type": "ScholarlyArticle", "name": "[The use of immunoglobulins and monoclonal antibodies against COVID-19].", "datePublished": "2024-05-06", "url": "https://questionsmedicales.fr/article/38843018", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.36233/0507-4088-225" } }, { "@type": "ScholarlyArticle", "name": "First-in-Human Phase 1 Randomized Trial with the Anti-CD40 Monoclonal Antibody KPL-404: Safety, Tolerability, Receptor Occupancy, and Suppression of T-Cell-Dependent Antibody Response.", "datePublished": "2023-09-12", "url": "https://questionsmedicales.fr/article/37699709", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1124/jpet.123.001771" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Acides aminés, peptides et protéines", "item": "https://questionsmedicales.fr/mesh/D000602" }, { "@type": "ListItem", "position": 3, "name": "Protéines", "item": "https://questionsmedicales.fr/mesh/D011506" }, { "@type": "ListItem", "position": 4, "name": "Globulines", "item": "https://questionsmedicales.fr/mesh/D005916" }, { "@type": "ListItem", "position": 5, "name": "Sérum-globulines", "item": "https://questionsmedicales.fr/mesh/D012712" }, { "@type": "ListItem", "position": 6, "name": "Immunoglobulines", "item": "https://questionsmedicales.fr/mesh/D007136" }, { "@type": "ListItem", "position": 7, "name": "Anticorps", "item": "https://questionsmedicales.fr/mesh/D000906" }, { "@type": "ListItem", "position": 8, "name": "Anticorps monoclonaux", "item": "https://questionsmedicales.fr/mesh/D000911" }, { "@type": "ListItem", "position": 9, "name": "Anticorps monoclonaux humanisés", "item": "https://questionsmedicales.fr/mesh/D061067" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Anticorps monoclonaux humanisés - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Anticorps monoclonaux humanisés", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2026-02-06", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Anticorps monoclonaux humanisés", "description": "Comment sont détectés les anticorps monoclonaux ?\nQuels tests sont utilisés pour évaluer leur efficacité ?\nPeut-on mesurer les niveaux d'anticorps dans le sang ?\nQuels biomarqueurs sont associés aux anticorps monoclonaux ?\nComment évaluer la réponse au traitement ?", "url": "https://questionsmedicales.fr/mesh/D061067#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Anticorps monoclonaux humanisés", "description": "Quels effets secondaires peuvent survenir ?\nLes anticorps monoclonaux causent-ils des douleurs ?\nY a-t-il des symptômes d'infection associés ?\nPeut-on avoir des réactions cutanées ?\nLes anticorps monoclonaux affectent-ils le système immunitaire ?", "url": "https://questionsmedicales.fr/mesh/D061067#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Anticorps monoclonaux humanisés", "description": "Les anticorps monoclonaux peuvent-ils prévenir des maladies ?\nComment sont-ils utilisés en prophylaxie ?\nY a-t-il des vaccins basés sur des anticorps monoclonaux ?\nPeut-on utiliser des anticorps monoclonaux en prévention des cancers ?\nLes anticorps monoclonaux sont-ils efficaces contre les variants viraux ?", "url": "https://questionsmedicales.fr/mesh/D061067#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Anticorps monoclonaux humanisés", "description": "Comment sont administrés les anticorps monoclonaux ?\nSont-ils utilisés en monothérapie ?\nQuel est le rôle des anticorps monoclonaux dans le cancer ?\nPeuvent-ils être utilisés pour des maladies auto-immunes ?\nY a-t-il des anticorps monoclonaux pour les infections virales ?", "url": "https://questionsmedicales.fr/mesh/D061067#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Anticorps monoclonaux humanisés", "description": "Quelles complications peuvent survenir avec ces traitements ?\nLes anticorps monoclonaux peuvent-ils provoquer des thromboses ?\nY a-t-il des risques de cancer associés ?\nComment gérer les effets indésirables graves ?\nLes anticorps monoclonaux peuvent-ils affecter la grossesse ?", "url": "https://questionsmedicales.fr/mesh/D061067#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Anticorps monoclonaux humanisés", "description": "Qui est à risque d'effets secondaires ?\nLes personnes âgées sont-elles plus à risque ?\nY a-t-il des facteurs génétiques influents ?\nLes comorbidités augmentent-elles les risques ?\nLes traitements antérieurs influencent-ils les résultats ?", "url": "https://questionsmedicales.fr/mesh/D061067#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment sont détectés les anticorps monoclonaux ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Ils sont détectés par des tests immunologiques spécifiques, comme l'ELISA." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer leur efficacité ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des études cliniques et des tests de réponse immunitaire sont utilisés." } }, { "@type": "Question", "name": "Peut-on mesurer les niveaux d'anticorps dans le sang ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des dosages sanguins peuvent quantifier les anticorps monoclonaux." } }, { "@type": "Question", "name": "Quels biomarqueurs sont associés aux anticorps monoclonaux ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Les biomarqueurs tumoraux comme le CA 15-3 peuvent être associés." } }, { "@type": "Question", "name": "Comment évaluer la réponse au traitement ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "La réponse est évaluée par imageries médicales et tests sanguins." } }, { "@type": "Question", "name": "Quels effets secondaires peuvent survenir ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les effets incluent des réactions allergiques, fatigue et nausées." } }, { "@type": "Question", "name": "Les anticorps monoclonaux causent-ils des douleurs ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Ils peuvent provoquer des douleurs au site d'injection ou des douleurs musculaires." } }, { "@type": "Question", "name": "Y a-t-il des symptômes d'infection associés ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des symptômes comme fièvre et frissons peuvent survenir." } }, { "@type": "Question", "name": "Peut-on avoir des réactions cutanées ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Des éruptions cutanées ou démangeaisons peuvent se produire." } }, { "@type": "Question", "name": "Les anticorps monoclonaux affectent-ils le système immunitaire ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils peuvent moduler la réponse immunitaire, augmentant le risque d'infections." } }, { "@type": "Question", "name": "Les anticorps monoclonaux peuvent-ils prévenir des maladies ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Ils peuvent prévenir certaines infections, comme dans le cas de traitements préventifs." } }, { "@type": "Question", "name": "Comment sont-ils utilisés en prophylaxie ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Ils sont administrés pour prévenir des infections chez les patients à risque." } }, { "@type": "Question", "name": "Y a-t-il des vaccins basés sur des anticorps monoclonaux ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Des recherches sont en cours pour développer des vaccins utilisant des anticorps monoclonaux." } }, { "@type": "Question", "name": "Peut-on utiliser des anticorps monoclonaux en prévention des cancers ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains anticorps sont explorés pour prévenir la récidive de cancers." } }, { "@type": "Question", "name": "Les anticorps monoclonaux sont-ils efficaces contre les variants viraux ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "L'efficacité peut varier selon le variant, nécessitant des études spécifiques." } }, { "@type": "Question", "name": "Comment sont administrés les anticorps monoclonaux ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Ils sont généralement administrés par voie intraveineuse ou sous-cutanée." } }, { "@type": "Question", "name": "Sont-ils utilisés en monothérapie ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Ils peuvent être utilisés seuls ou en association avec d'autres traitements." } }, { "@type": "Question", "name": "Quel est le rôle des anticorps monoclonaux dans le cancer ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Ils ciblent des cellules cancéreuses spécifiques pour inhiber leur croissance." } }, { "@type": "Question", "name": "Peuvent-ils être utilisés pour des maladies auto-immunes ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains anticorps monoclonaux traitent des maladies comme la polyarthrite rhumatoïde." } }, { "@type": "Question", "name": "Y a-t-il des anticorps monoclonaux pour les infections virales ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains anticorps monoclonaux sont développés pour traiter des infections virales comme COVID-19." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec ces traitements ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications incluent des infections, des réactions allergiques sévères et des effets secondaires." } }, { "@type": "Question", "name": "Les anticorps monoclonaux peuvent-ils provoquer des thromboses ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains traitements peuvent augmenter le risque de thromboses." } }, { "@type": "Question", "name": "Y a-t-il des risques de cancer associés ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Des études suggèrent un risque potentiel accru de certains cancers avec certains anticorps." } }, { "@type": "Question", "name": "Comment gérer les effets indésirables graves ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Les effets indésirables graves nécessitent une évaluation médicale immédiate." } }, { "@type": "Question", "name": "Les anticorps monoclonaux peuvent-ils affecter la grossesse ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Certains anticorps peuvent avoir des effets sur la grossesse, nécessitant une évaluation." } }, { "@type": "Question", "name": "Qui est à risque d'effets secondaires ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les patients avec des antécédents d'allergies ou d'infections sont à risque." } }, { "@type": "Question", "name": "Les personnes âgées sont-elles plus à risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les personnes âgées peuvent avoir un risque accru d'effets secondaires." } }, { "@type": "Question", "name": "Y a-t-il des facteurs génétiques influents ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Des variations génétiques peuvent influencer la réponse aux anticorps monoclonaux." } }, { "@type": "Question", "name": "Les comorbidités augmentent-elles les risques ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les comorbidités comme le diabète peuvent augmenter les risques d'effets indésirables." } }, { "@type": "Question", "name": "Les traitements antérieurs influencent-ils les résultats ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les traitements antérieurs peuvent affecter l'efficacité des anticorps monoclonaux." } } ] } ] }